155 related articles for article (PubMed ID: 25239464)
1. Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.
Calin R; Fourati S; Schneider L; Gautheret-Dejean A; Lambert-Niclot S; Wirden M; Carcelain G; Katlama C; Marcelin AG; Tubiana R
J Antimicrob Chemother; 2015 Jan; 70(1):317-9. PubMed ID: 25239464
[No Abstract] [Full Text] [Related]
2. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
3. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
4. Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus.
Kloosterboer N; Groeneveld PH; Jansen CA; van der Vorst TJ; Koning F; Winkel CN; Duits AJ; Miedema F; van Baarle D; van Rij RP; Brinkman K; Schuitemaker H
Virology; 2005 Aug; 339(1):70-80. PubMed ID: 15987650
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
6. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
8. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
9. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
10. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
[TBL] [Abstract][Full Text] [Related]
11. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.
Ghosn J; Deveau C; Chaix ML; Goujard C; Galimand J; Zitoun Y; Allègre T; Delfraissy JF; Meyer L; Rouzioux C;
J Antimicrob Chemother; 2010 Apr; 65(4):741-8. PubMed ID: 20167586
[TBL] [Abstract][Full Text] [Related]
12. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
[TBL] [Abstract][Full Text] [Related]
14. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F
J Infect Dis; 2012 May; 205(10):1520-8. PubMed ID: 22427678
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
[TBL] [Abstract][Full Text] [Related]
17. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
18. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
[TBL] [Abstract][Full Text] [Related]
19. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
[TBL] [Abstract][Full Text] [Related]
20. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
Ballana E; Riveira-Munoz E; Pou C; Bach V; Parera M; Noguera M; Santos JR; Badia R; Casadellà M; Clotet B; Paredes R; Martínez MA; Brander C; Esté JA
Immunobiology; 2013 Apr; 218(4):543-7. PubMed ID: 22818666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
